文献速递流行病学与生物统计

2015至2019年六种主要期刊发表的儿科随机对照试验参与者保留情况:系统综述与Meta分析

Participant retention in paediatric randomised controlled trials published in six major journals 2015-2019: systematic review and meta-analysis.
PubMed 文献 · Trials · 2023-06-14

该系统综述与Meta分析通过MEDLINE检索2015至2019年六种高影响因子医学期刊发表的儿科随机对照试验,纳入94项试验,中位总保留率为0.92(四分位距0.83至0.98),采用单变量随机效应Meta回归分析探讨背景与设计因素与保留率的关联。

要点

  • 纳入94项儿科随机对照试验,中位总保留率为0.92(四分位距0.83至0.98)。
  • 主要结局前有5次及以上随访评估、随机化至主要结局不足6个月、使用非主动数据收集方法的试验保留率估计更高。
  • 涉及11岁及以上儿童的试验保留率估计高于涉及更年幼儿童的试验。

核心结论

  • 已发表的儿科随机对照试验很少报告使用改善保留率的特定可调整因素。
  • 在主要结局前纳入多次定期随访可能减少脱落。
  • 当主要结局在参与者入组后至多6个月收集时,保留率可能最高。
  • 作者认为,针对涉及多个参与者(如年轻人及其照护者或教师)的试验如何改善保留率开展定性研究是值得的。
  • 设计儿科试验者还需考虑使用适当的参与方法。

研究设计与样本

  • 系统综述与Meta分析,使用MEDLINE数据库识别2015至2019年发表于六种综合与专科高影响因子医学期刊的儿科随机对照试验。
  • 纳入94项试验,审查结局为每项试验主要结局的参与者保留率。
  • 提取背景因素(如人群、疾病)与设计因素(如试验时长),依次检验各因素与保留率的关联,采用单变量随机效应Meta回归分析判定关联证据。

主要发现

  • 94项试验的中位总保留率为0.92(四分位距0.83至0.98)。
  • 主要结局前有5次及以上随访评估的试验、随机化至主要结局不足6个月的试验、使用非主动数据收集方法的试验,保留率估计更高。
  • 涉及11岁及以上儿童的试验保留率估计高于涉及更年幼儿童的试验。
  • 不涉及其他参与者的试验保留率高于涉及其他参与者的试验。
  • 使用主动或安慰剂对照治疗的试验保留率估计高于常规治疗试验;使用至少一种参与方法的试验保留率增加。

关键数值与推荐

  • 与纳入所有年龄段参与者的试验综述不同,本综述未发现保留率与治疗组数量、试验规模或治疗类型之间存在关联。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The factors which influence participant retention in paediatric randomised controlled trials are under-researched. Retention may be more challenging due to child developmental stages, involving additional participants, and proxy-reporting of outcomes. This systematic review and meta-analysis explores the factors which may influence retention in paediatric trials. METHODS: Using the MEDLINE database, paediatric randomised controlled trials published between 2015 and 2019 were identified from six general and specialist high-impact factor medical journals. The review outcome was participant retention for each reviewed trial's primary outcome. Context (e.g. population, disease) and design (e.g. length of trial) factors were extracted. Retention was examined for each context and design factor in turn, with evidence for an association being determined by a univariate random-effects meta-regression analysis. RESULTS: Ninety-four trials were included, and the median total retention was 0.92 (inter-quartile range 0.83 to 0.98). Higher estimates of retention were seen for trials with five or more follow-up assessments before the primary outcome, those less than 6 months between randomisation and primary outcome, and those that used an inactive data collection method. Trials involving children aged 11 and over had the higher estimated retention compared with those involving younger children. Those trials which did not involve other participants also had higher retention, than those where they were involved. There was also evidence that a trial which used an active or placebo control treatment had higher estimated retention, than treatment-as-usual. Retention increased if at least one engagement method was used. Unlike reviews of trials including all ages of participants, we did not find any association between retention and the number of treatment groups, size of trial, or type of treatment. CONCLUSIONS: Published paediatric RCTs rarely report the use of specific modifiable factors that improve retention. Including multiple, regular follow-ups with participants before the primary outcome may reduce attrition. Retention may be highest when the primary outcome is collected up to 6 months after a participant is recruited. Our findings suggest that qualitative research into improving retention when trials involve multiple participants such as young people, and their caregivers or teachers would be worthwhile. Those designing paediatric trials also need to consider the use of appropriate engagement methods. RESEARCH ON RESEARCH (ROR) REGISTRY: https://ror-hub.org/study/2561.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Gaunt DM, Papastavrou Brooks C, Pedder H, et al. Participant retention in paediatric randomised controlled trials published in six major journals 2015-2019: systematic review and meta-analysis. Trials. 2023. PMID: 37316945. doi:10.1186/s13063-023-07333-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。